14 April 2021, 10:00 pm EDT By
The Adenovirus ingredient found in COVID-19 vaccines from Johnson &Johnson (J&J) and AstraZeneca has been one of the top talks of the town as it causes alarm and a dangerous side effect. The use of the virus is to help the delivery and effectiveness of a vaccine as it enters the human body, making people immune to the disease to fight against it.
(Photo : Screenshot From @DiarioDeTabasco From Twitter)
In the recent developments of the coronavirus pandemic, vaccines from Pfizer and BioNTech, and Moderna have been released for Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA). It has also been supported by the Center for Disease Control and Prevention (CDC), but new players like Oxford s AstraZeneca and J&J are slowly making their way.
Apr 14, 2021
TUESDAY, April 13, 2021 (HealthDay News) While rare, thrombosis and thrombocytopenia can occur after the ChAdOx1 nCoV-19 adenoviral vector vaccine against COVID-19 (AstraZeneca), according to two reports published online April 9 in the
New England Journal of Medicine.
Andreas Greinacher, M.D., from Universitätsmedizin Greifswald in Germany, and colleagues assessed the clinical and laboratory features of 11 patients (nine women; median age, 36 years) in Germany and Austria experiencing thrombosis or thrombocytopenia after vaccination with ChAdOx1 nCov-19. Thrombotic events occurred five to 16 days after vaccination in all except one patient, and six of these patients died. The researchers conclude that vaccination can result in the rare development of immune thrombotic thrombocytopenia mediated by platelet-activating antibodies against platelet factor 4 (PF4), which clinically mimics autoimmune heparin-induced thrombocytopenia.
April 09, 2021
One of the first papers to document the rare thrombotic events seen in Austria and Germany involving a form of thrombocytopenia after inoculation with the vaccine jointly developed by the University of Oxford and AstraZeneca has now been published in the
New England Journal of Medicine, accompanied by a brief report confirming similar findings in a Norwegian cohort.
Taken together the papers show a clear link between this particular vaccine and the ”clotting abnormalities” that have led countries around the world to pause or revise their plans for the use of the Oxford/AstraZeneca product. Critically, say authors, the reports also point the way for definitive testing with widely available tests that would permit affected patients to be swiftly identified and treated, potentially averting serious thrombotic events.
email article
Following up on previous reviews of the evidence, the European Medicines Agency (EMA), WHO, and Britain s Medicine s and Healthcare Products Regulatory Agency (MHRA) have issued statements saying that the overall benefits continue to outweigh the risks of very rare blood clots with low platelets reported after the AstraZeneca COVID-19 vaccine.
The WHO now states that a causal relationship is considered plausible but is not confirmed, while the MHRA has said that the evidence is now stronger for a link between the vaccine and these events. The EMA calls these unusual blood clots with low platelets and says they should be listed as very rare side effects of the vaccine.